RNTX on Nasdaq
Rein Therapeutics, Inc.
In its 2026 annual report the company says: “We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03.”3 It is headquartered in Austin, Texas.1 Its shares trade on Nasdaq under the symbol RNTX.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerRNTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersAustin, Texas1
- Business address12407 N. Mopac Expy., Suite 250 #390, Austin, Tx 787582
- Filer categoryNon-accelerated filer, Smaller reporting company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03. Our pipeline includes:3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-294.8%Return on equity4
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $11.0M | $14.2M |
| General and administrative | $10.9M | $13.9M |
| Impairment loss on intangible assets | $28.7M | $37.0M |
| Total operating expenses | $50.6M | $65.1M |
| Loss from operations | -$50.6M | -$65.1M |
| Other income, net | $48.0K | $685.0K |
| Income tax benefit | $712.0K | $1.5M |
| Net loss | -$49.9M | -$62.9M |
| Net loss per share - basic | -$1.96 | -$3.51 |
| Net loss per share - diluted | -$1.96 | -$3.51 |
| Weighted average common shares outstanding - basic | 25.4M shares | 17.9M shares |
| Weighted average common shares outstanding - diluted | 25.4M shares | 17.9M shares |
| Unrealized (loss) gain on investments, net of tax of $0 | -$15.0K | $45.0K |
| Foreign currency translation adjustments | -$29.0K | $0 |
| Total other comprehensive (loss) gain | -$44.0K | $45.0K |
| Total comprehensive loss | -$49.9M | -$62.8M |
| Unrealized gain on investments, tax | $0 | $0 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.2M | $12.9M | $17.3M |
| Prepaid expenses and other current assets | $1.1M | $792.0K | |
| Total current assets | $4.3M | $13.7M | |
| Property and equipment, net | $0 | $1.0K | |
| Goodwill | $6.3M | $6.3M | |
| Intangible assets | $13.5M | $42.2M | |
| Other non-current assets | $2.0K | $2.0K | |
| Total assets | $24.2M | $62.2M | |
| Accounts payable | $4.0M | $911.0K | |
| Accrued expenses and other current liabilities | $2.2M | $4.8M | |
| Total current liabilities | $6.2M | $5.7M | |
| Deferred tax liability | $1.1M | $1.8M | |
| Other long-term liability | $0 | $277.0K | |
| Total liabilities | $7.2M | $7.8M | |
| Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 24,610 shares issued and 12,232 shares outstanding at December 31, 2025 and at December 31, 2024 | $45.0M | $45.0M | |
| Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 27,550,222 shares and 21,666,012 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $113.0K | $108.0K | |
| Additional paid-in capital | $373.1M | $360.7M | |
| Accumulated other comprehensive loss | -$62.0K | -$18.0K | |
| Accumulated deficit | -$401.3M | -$351.4M | |
| Total liabilities, convertible preferred stock and stockholders' equity | $24.2M | $62.2M | |
| Convertible preferred stock, par value | $0.00 | $0.00 | |
| Convertible preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Convertible preferred stock, shares issued | 24.6K shares | 24.6K shares | |
| Convertible preferred stock, shares outstanding | 12.2K shares | 12.2K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 27.6M shares | 21.7M shares | |
| Common stock, shares outstanding | 27.6M shares | 21.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.2M | $12.9M | $17.3M |
| Prepaid expenses and other current assets | $1.1M | $792.0K | |
| Total current assets | $4.3M | $13.7M | |
| Property and equipment, net | $0 | $1.0K | |
| Goodwill | $6.3M | $6.3M | |
| Intangible assets | $13.5M | $42.2M | |
| Other non-current assets | $2.0K | $2.0K | |
| Total assets | $24.2M | $62.2M | |
| Accounts payable | $4.0M | $911.0K | |
| Accrued expenses and other current liabilities | $2.2M | $4.8M | |
| Total current liabilities | $6.2M | $5.7M | |
| Deferred tax liability | $1.1M | $1.8M | |
| Other long-term liability | $0 | $277.0K | |
| Total liabilities | $7.2M | $7.8M | |
| Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 24,610 shares issued and 12,232 shares outstanding at December 31, 2025 and at December 31, 2024 | $45.0M | $45.0M | |
| Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 27,550,222 shares and 21,666,012 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $113.0K | $108.0K | |
| Additional paid-in capital | $373.1M | $360.7M | |
| Accumulated other comprehensive loss | -$62.0K | -$18.0K | |
| Accumulated deficit | -$401.3M | -$351.4M | |
| Total liabilities, convertible preferred stock and stockholders' equity | $24.2M | $62.2M | |
| Convertible preferred stock, par value | $0.00 | $0.00 | |
| Convertible preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Convertible preferred stock, shares issued | 24.6K shares | 24.6K shares | |
| Convertible preferred stock, shares outstanding | 12.2K shares | 12.2K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 27.6M shares | 21.7M shares | |
| Common stock, shares outstanding | 27.6M shares | 21.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$49.9M | -$62.9M |
| Commitment fee related to Pre-Paid Advance agreement | $300.0K | $0 |
| Original issue discount related to Pre-Paid Advance agreement | $150.0K | $0 |
| Depreciation and amortization expense | $1.0K | $63.0K |
| Stock-based compensation expense | $2.2M | $1.1M |
| Impairment loss on intangible assets | $28.7M | $37.0M |
| Prepaid expenses and other current assets | -$319.0K | $134.0K |
| Other assets | $0 | $2.2M |
| Accounts payable | $3.1M | -$279.0K |
| Operating lease liabilities | $0 | -$48.0K |
| Accrued expenses and other current liabilities | -$2.6M | $1.7M |
| Other long-term liabilities | -$277.0K | $277.0K |
| Deferred tax liabilities | -$712.0K | -$1.6M |
| Net cash used in operating activities | -$19.4M | -$22.3M |
| Proceeds from issuance of common stock, net of offering costs | $1.8M | $10.6M |
| Proceeds from Pre-Paid Advances, net of discounts | $2.9M | $0 |
| Proceeds from issuance of common stock in connection with stock option exercises | $4.0K | $143.0K |
| Proceeds from issuance of common stock in connection with Warrant Exercises, net of costs | $1.6M | $0 |
| Proceeds from issuance of warrants, net of offering costs | $481.0K | $7.0M |
| Proceeds from Warrant Exchanges, net of offering costs | $3.0M | $0 |
| Proceeds from warrant exercises with common stock subscribed | $22.0K | $0 |
| Net cash provided by financing activities | $9.8M | $17.8M |
| Effect of exchange rate changes on cash and cash equivalents | -$44.0K | $0 |
| Net decrease in cash and cash equivalents | -$9.7M | -$4.5M |
| Unrealized (loss) gain on short-term investments | -$15.0K | $37.0K |
| Foreign currency translation adjustments | -$29.0K | $0 |
| Issuance of common stock for Pre-Paid Advances and interest accrual | $3.0M | $0 |
| Conversion of Series X non-voting convertible preferred stock into common stock shares | $0 | $46.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Rein Therapeutics, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Rein Therapeutics, Inc.
- ADAR1 Capital Management, LLC Filed SCHEDULE 13G on Rein Therapeutics, Inc., latest Aug 14, 2026
- Lynwood Capital Management Inc. Filed SCHEDULE 13G/A on Rein Therapeutics, Inc., latest Aug 14, 2026 (2 filings since May 8, 2026)
- Laurence W. Lytton Filed SCHEDULE 13G/A on Rein Therapeutics, Inc., latest Aug 13, 2026 (2 filings since May 6, 2026)
- Voss Capital, LP Filed SCHEDULE 13G/A on Rein Therapeutics, Inc., latest Jul 14, 2026 (4 filings since May 14, 2025)
- BIOS Fund I, LP Filed SCHEDULE 13G/A on Rein Therapeutics, Inc., latest May 8, 2026 (2 filings since Nov 13, 2023)
- Funicular Funds, LP Filed SCHEDULE 13G on Rein Therapeutics, Inc., latest May 7, 2026
- UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO Filed SCHEDULE 13G/A on Rein Therapeutics, Inc., latest Nov 5, 2024 (2 filings since Mar 5, 2024)
- Muneer A. Satter Filed SC 13D/A on Rein Therapeutics, Inc., latest Apr 16, 2024 (3 filings since Nov 3, 2023)
- BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Rein Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
- Scott Kapnick Filed SC 13G/A on Rein Therapeutics, Inc., latest Feb 5, 2024 (3 filings since Feb 14, 2022)
- Rein Therapeutics, Inc. Austin, Texas
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Rein Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $6.3M4 Dec 31, 2025 | $6.3M4 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $13.5M4 Dec 31, 2025 | $42.2M4 Dec 31, 2024 | −68.0% |
| Indefinite-lived intangibles (excluding goodwill) | $13.5M4 Dec 31, 2025 | $42.2M4 Dec 31, 2024 | −68.0% |
Properties, in its own words
On August 16, 2021, Lung entered into an operating lease agreement to rent approximately 6,455 square feet of office space for its corporate headquarters in Austin, Texas, beginning on October 1, 2021. The lease expired March 31, 2024, and we did not renew the lease. Following expiration of the lease, we are operating virtually, and expect to do so for the foreseeable future. Our current address is used solely as a mailing address for the receipt of correspondence.
Item 2 of the 10-K filed Mar 26, 2026.3
Leadership
Who has led Rein Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20202025
- Chief executive officerJames Brian Windsor Dec 4, 2024 to now12
- Chief executive officerJohn P. Longenecker Phd. May 17, 2018 to Aug 14, 201813
- Chief executive officerManuel Aivado Sep 7, 2018 to Apr 17, 201914
- PresidentJames Brian Windsor Nov 21, 2023 to now15
- PresidentJohn P. Longenecker Phd. May 17, 2018 to Aug 14, 201813
- PresidentManuel Aivado Sep 7, 2018 to Apr 17, 201914
- Chief financial officerDonald Dougherty Jun 28, 2017 to Apr 17, 201916
- Chief operating officerJames Brian Windsor Nov 21, 2023 to Mar 6, 202415
Board members and other officers (28)
- OfficerTimothy M. Cunningham May 16, 2024 to May 16, 202417
- OfficerJames Brian Windsor Nov 2, 2023 to now18
- OfficerSusan L. Drexler Jun 17, 2022 to Jun 17, 202219
- OfficerMuneer A. Satter Jan 8, 2021 to Jan 8, 202120
- SVP, Chief Business OfficerKathryn Gregory Feb 25, 2019 to Feb 4, 202021
- VP, Finance and OperationsRick Wanstall Apr 3, 2019 to Mar 30, 202222
- OfficerAllen Annis Nov 6, 2018 to Mar 30, 202223
- SVP, Chief Medical OfficerVojo Vukovic Nov 6, 2018 to Mar 30, 202224
- OfficerJoseph A. Yanchik Iii. Jun 28, 2017 to Jul 27, 201725
- OfficerKira Nelson Jun 28, 2017 to Jul 27, 201726
- OfficerManuel Aivado Jun 28, 2017 to Mar 30, 202227
- Board memberJames Brian Windsor May 13, 2026 to now28
- Board memberAlan A. Musso Nov 2, 2023 to now29
- Board memberWilliam Fairey Nov 2, 2023 to now30
- Board memberMuneer A. Satter Jun 9, 2020 to Jan 8, 202131
- Board memberNolan Howard Sigal Apr 3, 2019 to Jun 17, 202232
- Board memberRickenbach Josef H. Von Jun 24, 2019 to now33
- Board memberWilliam McKee Jun 24, 2019 to Jun 17, 202234
- Board memberJeffrey Allen Bailey Mar 19, 2018 to Jun 17, 202235
- Board memberManuel Aivado Sep 7, 2018 to now14
- Board memberArmen Shanafelt Jun 28, 2017 to Jun 25, 201836
- Board memberBrian M. Gallagher Jr. Jun 28, 2017 to Jul 27, 201737
- Board memberCaleb Maxfield Winder Jun 28, 2017 to Jun 25, 201838
- Board memberJodie Pope Morrison Jun 28, 2017 to Jun 17, 202239
- Board memberJohn H. McArthur Jun 28, 2017 to Jun 21, 201940
- Board memberJoseph A. Yanchik Iii. Jun 28, 2017 to Jul 27, 201725
- Board memberReinhard J. Ambros Jun 28, 2017 to now41
- Board memberScott Kapnick Jun 28, 2017 to Aug 14, 201842
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
- Sep 4, 20268-K Regulation FD disclosure44
- Aug 27, 20268-K Listing notice or transfer45
- Jul 21, 20268-K Shareholder vote46
- May 4, 20268-K Entered a material agreement; Other events47
- Mar 2, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares48
- Feb 19, 20268-K Executive or director change49
- Jan 16, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares50
- Dec 11, 20258-K Ended a material agreement51
- Nov 3, 20258-K Other events52
- Oct 24, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares53
- Oct 9, 20258-K Other events54
- Sep 22, 20258-K Other events55
- Dec 4, 2024New chief executive James Brian Windsor becomes CEO12
- Sep 7, 2018New chief executive Manuel Aivado becomes CEO14
- May 17, 2018New chief executive John P. Longenecker Phd. becomes CEO13
Calendar
Coming up
- Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.21) a share, on Nov 14, 2025.56
When it reported results
- May 15, 2025Reported quarterly or annual results57
- Nov 14, 2024Reported quarterly or annual results58
- Aug 14, 2024Reported quarterly or annual results59
- May 15, 2024Reported quarterly or annual results60
- May 1, 2024Reported quarterly or annual results61
- Apr 15, 2024Reported quarterly or annual results62
Drug trials and FDA: coming up
- Sep 30, 2027Phase 2 trial readout expected Phase 2 trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF): primary completion expected Sep 30, 2027 (ClinicalTrials.gov NCT06968845).63
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
214 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 53 major events, 57 insider forms, 22 large holders, 1 private raises, 57 other. The latest 20:
- Sep 4, 20268-K EDGAR
- Aug 27, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Jul 21, 20268-K EDGAR
- Jul 14, 2026SCHEDULE 13G/A EDGAR
- Jun 8, 2026ARS EDGAR
- Jun 8, 2026DEFA14A EDGAR
- Jun 8, 2026DEF 14A EDGAR
- May 28, 20264 EDGAR
- May 28, 2026PRE 14A EDGAR
- May 15, 202610-Q EDGAR
- May 13, 20264 EDGAR
- May 8, 2026SCHEDULE 13G/A EDGAR
- May 8, 2026SCHEDULE 13G EDGAR
- May 7, 2026SCHEDULE 13G EDGAR
- May 6, 2026SCHEDULE 13G EDGAR
- May 4, 20268-K EDGAR
The 214 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
24 open-market trades by officers, directors and large owners since October 2021: 12 buys and 12 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 27, 2026 | VON RICKENBACH JOSEF HDirector | Buy | 4,500 | $1.07 | $4.8K | Form 4 |
| May 26, 2026 | VON RICKENBACH JOSEF HDirector | Buy | 23,190 | $1.06 | $24.6K | Form 4 |
| May 22, 2026 | VON RICKENBACH JOSEF HDirector | Buy | 15,950 | $1.05 | $16.7K | Form 4 |
| May 21, 2026 | VON RICKENBACH JOSEF HDirector | Buy | 3,420 | $1.04 | $3.6K | Form 4 |
| Apr 30, 2026 | WINDSOR JAMES BRIANSee Remarks | Buy | 25,000 | $1.00 | $25.0K | Form 4 |
| Nov 14, 2025 | Voss Value Master Fund, LP10% owner | Buy | 104,183 | $1.22 | $127.1K | Form 4 |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP10% owner | Buy | 178,392 | $1.39 | $248.0K | Form 4 |
| Oct 27, 2025 | Voss Value-Oriented Special Situations Fund, LP10% owner | Buy | 97,482 | $1.37 | $133.6K | Form 4 |
| Oct 24, 2025 | Voss Value-Oriented Special Situations Fund, LP10% owner | Buy | 30,176 | $1.39 | $41.9K | Form 4 |
| Dec 5, 2024 | WINDSOR JAMES BRIANSee Remarks | Buy | 400 | $2.24 | $898 | Form 4 |
| Jun 17, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 4,707 | $3.25 | $15.3K | Form 4 |
| Jun 14, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 1,900 | $3.30 | $6.3K | Form 4 |
| Jun 12, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 9,342 | $3.25 | $30.4K | Form 4 |
| Jun 11, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 5,752 | $3.26 | $18.7K | Form 4 |
| Jun 10, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 9,577 | $3.30 | $31.6K | Form 4 |
| Jun 7, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 1,740 | $3.26 | $5.7K | Form 4 |
| Jun 6, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 4,284 | $3.29 | $14.1K | Form 4 |
| Jun 5, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 6,291 | $3.30 | $20.8K | Form 4 |
| May 1, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 20,315 | $4.21 | $85.5K | Form 4 |
| May 1, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% owner | Sale | 20,315 | $4.21 | $85.5K | Form 4 |
All 24 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ADAR1 Capital Management, LLCSCHEDULE 13G, 1 filing Aug 14, 202664
- Lynwood Capital Management Inc.SCHEDULE 13G/A, 2 filings May 8, 2026 to Aug 14, 202665
- Laurence W. LyttonSCHEDULE 13G/A, 2 filings May 6, 2026 to Aug 13, 202666
- Voss Capital, LPSCHEDULE 13G/A, 4 filings May 14, 2025 to Jul 14, 202667
- BIOS Fund I, LPSCHEDULE 13G/A, 2 filings Nov 13, 2023 to May 8, 202668
- Funicular Funds, LPSCHEDULE 13G, 1 filing May 7, 202669
- UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT COSCHEDULE 13G/A, 2 filings Mar 5, 2024 to Nov 5, 202470
- Muneer A. SatterSC 13D/A, 3 filings Nov 3, 2023 to Apr 16, 202471
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202472
- Scott KapnickSC 13G/A, 3 filings Feb 14, 2022 to Feb 5, 202473
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Brian WindsorPh.D. | $575.0K | $882.7K74 | |
| 2025 | Timothy M. Cunningham | 64 | $433.9K74 | |
| 2024 | President and Chief Executive Officer | $506.2K | $1.8M74 | |
| 2024 | Interim Chief Financial Officer | $275.6K74 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $18.3M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2023 | $18.3M | $18.3M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 59. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Rein Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRein Therapeutics, Inc.1
- CIK0001420565
- Employer ID (EIN)13-41960173
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address12407 N. Mopac Expy., Suite 250 #390, Austin, TX 787581
- Phone73780219891
- Shares outstanding86,267,032 as of Aug 12, 202611
- Public float$32.3M as of Jun 30, 20253
- AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceDec 3, 20071
- Filings525 in all: 4 (156), 8-K (88), 3 (43), 10-Q (28), 424B5 (16), CORRESP (15), SC 13D/A (15), UPLOAD (13)1
All 44 form types
EFFECT (12), SC 13G/A (12), DEFA14A (11), 10-K (9), DEF 14A (9), 4/A (8), S-8 (8), SC 13G (8), SCHEDULE 13G/A (7), S-3 (6), 10-K/A (5), D (5), PRE 14A (5), S-1 (5), SC 13D (5), SCHEDULE 13G (5), ARS (4), DRS/A (4), CT ORDER (2), DRS (2), DRSLTR (2), NT 10-K (2), S-1/A (2), 144 (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DEL AM (1), FWP (1), POS AM (1), REGDEX (1), REGDEX/A (1), S-3/A (1)
- Latest filingsAnnual report (10-K) Mar 26, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Jun 8, 2026
Latest 8-K (8-K) Sep 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value | RNTX | Nasdaq |
From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Rein Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 68 risks under these headings, as written.3
- Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K and in other documents that we file with the SEC, in evaluating our company and our business. Investing in our common stock involves a high degree of risk. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.
- Risks Related to Our Financial Condition
- We require substantial additional capital to finance our operations. Our cash and cash equivalents are not sufficient to enable us to sustain our operations beyond the second quarter of 2026 or complete the development and commercialization of LTI-03. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our clinical and research and development programs, future commercialization efforts or other operations.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to LTI-03, LTI-01 or other product candidates.
- We have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our prospects and likelihood of success.
- We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future and do not expect to achieve or maintain profitability; Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
- Global and macroeconomic developments can disrupt our supply chains and adversely affect our financial condition and results of operations.
- We have identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future or fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.
- We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail.
- Risks Related to the Discovery, Development and Commercialization of Product Candidates
- Our business is highly dependent on the success of our lead product candidate, LTI-03.
- Our approach to drug research and development in the area of fibrotic diseases, with a focus on Cav1-related peptides, is unproven and may not result in marketable products.
The other 58 risks
- The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.
- We are conducting and may in the future choose to conduct clinical trials for current or future product candidates outside of the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of LTI-03.
- Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies or earlier clinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates.
- Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome.
- If we encounter difficulties enrolling and retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- If approved, our product candidates that are regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
- Although we have received U.S. and EU Orphan Drug Designation for LTI-03 for IPF and U.S. and EU Orphan Drug Designation for LTI-01 for pleural empyema, we may be unable to obtain and maintain Orphan Drug Designation for our other product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.
- We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.
- If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates.
- Risks Related to Marketing Approval
- We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.
- Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of LTI-03, LTI-01 or any other product candidate that we may develop. As a result, we cannot predict when or if, and in which territories or for which indications, we, or any future collaborators, will obtain marketing approval to commercialize LTI-03, LTI-01 or any other product candidate that we may develop.
- Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for LTI-03 or LTI-01 in the U.S. would not assure approval of our product candidates in foreign jurisdictions.
- The design or execution of our ongoing and future clinical trials may not support marketing approval.
- If the FDA or comparable foreign regulatory authorities approve generic or competitor versions of any of our drugs that receive marketing approval, or such authorities do not grant our drugs appropriate periods of data or market exclusivity before approving generic or competitor versions of our drugs, the sales of our drugs could be adversely affected.
- Risks Related to Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
- Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates, if approved.
- We may seek to obtain certain regulatory designations for our product candidates. We may not receive such designations, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.
- Accelerated approval by the FDA, even if granted for any of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- Additional laws and regulations governing international operations could negatively impact or restrict our operations.
- Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.
- We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
- Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Risks Related to Our Dependence on Third Parties
- We rely on third parties to conduct certain aspects of our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.
- Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
- We depend on sole-source third-party suppliers for materials that are necessary for the conduct of preclinical studies and manufacture of our product candidates for clinical trials, and the loss of these third-party suppliers and manufacturers or their inability to supply us with sufficient quantities of adequate materials, or to do so at acceptable quality levels and on a timely basis, could harm our business.
- Risks Related to Our Intellectual Property
- Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.
- We are currently party to license or other collaboration agreements that impose certain obligations on us, and we may enter into additional license or collaboration agreements in the future. If we fail to comply with our obligations under such present or future agreements with third parties, we could lose license rights that may be important to our business.
- Reliance on third parties requires us to share our proprietary information, which increases the possibility that such information will be misappropriated or disclosed.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.
- We may not be able to protect our intellectual property rights throughout the world.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our use of samples or other materials, which they provide to us, or otherwise arising from the collaboration.
- We may be subject to claims challenging the inventorship of our patents and other intellectual property.
- Third parties may assert that we are employing their proprietary technology without authorization, infringing, misappropriating, or otherwise violating their intellectual property rights. We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
- Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
- Any current or future patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
- Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Risks Related to Employee Matters and Managing Growth
- Our internal computer systems, or those of our vendors or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
- Risks Related to Our Common Stock
- If we fail to maintain compliance with the requirements for continued listing on the Nasdaq Capital Market, our common stock could be delisted from trading, which would adversely affect the liquidity of our common stock.
- An active trading market for our common stock may not be sustained.
- If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
- The price of our stock may be volatile, and you could lose all or part of your investment.
- We could be subject to securities class action litigation.
- Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- A significant portion of our total outstanding shares may be sold into the market at any time, which could cause the market price of our common stock to drop significantly, even if our business is doing well.
- Assuming the conversion of all outstanding Series X Preferred Stock and the exercise of outstanding warrants, there is a concentration of ownership of our outstanding common stock by one group of affiliated stockholders. If this group chooses to act together, it could exert substantial influence over our business, and the interests of this group may conflict with those of other stockholders.
- Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.
Legal proceedings
We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse impact on us because of defense and settlement, costs, diversion of management resources, and other factors.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJames Brian Windsor, President
- 16
- 17SEC EDGARTimothy M. Cunningham, Officer
- 18SEC EDGARJames Brian Windsor, Officer
- 19SEC EDGARSusan L. Drexler, Officer
- 20SEC EDGARMuneer A. Satter, Officer
- 21
- 22
- 23SEC EDGARAllen Annis, Officer
- 24
- 25SEC EDGARJoseph A. Yanchik Iii., Officer
- 26SEC EDGARKira Nelson, Officer
- 27SEC EDGARManuel Aivado, Officer
- 28SEC EDGARJames Brian Windsor, Board member
- 29SEC EDGARAlan A. Musso, Board member
- 30SEC EDGARWilliam Fairey, Board member
- 31SEC EDGARMuneer A. Satter, Board member
- 32SEC EDGARNolan Howard Sigal, Board member
- 33
- 34SEC EDGARWilliam McKee, Board member
- 35SEC EDGARJeffrey Allen Bailey, Board member
- 36SEC EDGARArmen Shanafelt, Board member
- 37SEC EDGARBrian M. Gallagher Jr., Board member
- 38SEC EDGARCaleb Maxfield Winder, Board member
- 39SEC EDGARJodie Pope Morrison, Board member
- 40SEC EDGARJohn H. McArthur, Board member
- 41SEC EDGARReinhard J. Ambros, Board member
- 42SEC EDGARScott Kapnick, Board member
- 43
- 44SEC EDGARRegulation FD disclosure
- 45SEC EDGARListing notice or transfer
- 46SEC EDGARShareholder vote
- 47
- 48
- 49SEC EDGARExecutive or director change
- 50
- 51SEC EDGAREnded a material agreement
- 52SEC EDGAROther events
- 53
- 54SEC EDGAROther events
- 55SEC EDGAROther events
- 56NasdaqNasdaq calendar
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74